Statins and nutraceuticals/functional food: Could they be combined?

Combination Therapy In Dyslipidemia

Volumn , Issue , 2015, Pages 127-142

  Cicero, Arrigo F G ^a   Colletti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955395314     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/9783319204338_11     Document Type: Chapter

References (95)

1. Ackermann RT, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813-824.
2. Affuso F, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol. 2012;4:77-83.
3. Anderson GD, et al. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003;43:643-648.
4. Anderson JW, et al. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
5. Berginc K, et al. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet. 2010;25(6):521-530.
6. Berthold HK, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized, controlled trial. JAMA. 2006;295:2262-2269
7. Brashears MM, et al. Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998;81:2103-2110.
8. Burcelin R, et al. The gut microbiota ecology: new opportunity for the treatment of metabolic diseases? Front Biosci. 2009;14:5107-5117.
9. Cambria-Kiely JA. Effect of soy milk on warfarin. Ann Pharmacother. 2002;36:1893-1896.
10. Cani PD, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58(8):1091-1103.
11. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonat. 1993;63:201-208
12. Chen ST, et al. Variable effects of soy protein on plasma lipids in hyperlipidemic and normo- lipidemic hemodialysis patients. Am J Kidney Dis. 2005;46:1099-1106.
13. Chua M, et al. Traditional uses and potential health benefits of Amorphophallus konjac K. Koch ex N.E.Br. J Ethnopharmacol. 2010;128:268-278.
14. Cicero AFG, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol. 2009;4(5):553-563.
15. Cicero AFG, et al. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med. 2005;13:273-278.
16. Cicero AFG, et al. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung. 2007;57:26-30.
17. Cicero AFG, et al. Long-term efficacy and tolerability of a largely marketed multicomponent nutra- ceutical in overweight and normoweight dyslipidaemic patients. Nutrafoods. 2012;11(2):15-21.
18. Cicero AFG, et al. Tolerability and safety of commonly used dietary supplements and nutra- ceuticals with lipid-lowering effects. Expert Opin Drug Saf. 2012;11(5):753-766. doi:10.1517/14740338.2012.705827.
19. Cicero AFG, et al. Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercho- lesterolemic patients with or without chronic kidney disease. Open Hypertens J. 2013;5:18-22.
20. Cicero AFG, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res. 2013;33(8):622-8. doi:10.1016/j.nutres.2013.05.01.
21. Cicero AFG, et al. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol. 2014;12(4):565-571.
22. Cicero AFG, et al. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev. 2014;21(3):221-226. doi:10.1007/s40292-014-0052-5.
23. Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev. 2007;25(4):375-390.
24. Derosa G, et al. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12(8):1113-1124.
25. Eisenbrand G. Toxicological evaluation of red mould rice. Mol Nutr Food Res. 2006;50: 322-327.
26. El Khoury D, Anderson GH. Recent advances in dietary proteins and lipid metabolism. Curr Opin Lipidol. 2013;24(3):207-213. doi:10.1097/M0L.0b013e3283613bb7.
27. Gheit O, et al. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Eur J Intern Med. 2009;20:e57-61.
28. Gliozzi M, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170(2):140-5. doi:10.1016/j.ijcard.2013.08.125.
29. Grieco A, et al. A cute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all. J Hepatol. 2009;50:1273-1277.
30. Grill JP, et al. Effects of Lactobacillus amylovorus and Bifidobacterium breve on cholesterol. Lett Appl Microbiol. 2000;31:154-156.
31. Grundy SM. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol. 2005;96(suppl):47D-50.
32. Guardamagna O, et al. Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption. Acta Diabetol. 2011;48:127-133.
33. Guo Z, et al. Influence of consumption of probiotics on the plasma Lipid profile: a metaanalysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844-850.
34. Gylling H, et al. The effect of a very high daily plant stanol ester intake on serum lipids, carot- enoids, and fat soluble vitamins. Clin Nutr. 2010;29:112-118.
35. Gylling H, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232(2):346-360. doi:10.1016/j. atherosclerosis.2013.11.043.
36. Halbert SC, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010; 105(2):198-204.
37. Harland JI, Haffner TA. Systematic review, meta-analysis and regression of randomized controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. Atherosclerosis. 2008;200:13-27.
38. Hutchins AM, et al. Hypertensive crisis associated with high dose soy isoflovane supplementation in a post-menopausal woman; a case report. BMC Womens Health. 2005;5:9.
39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. A systematic review. Drugs. 2001;61:2163-2175.
40. Kang Q, Chen A. Curcumin suppresses expression of low-density lipoprotein receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol. 2009;157:1354-1367.
41. Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30-34.
42. Keithley J, et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition. 2002;18:201-204.
43. Klaver FA, Van der Meer V. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt -deconjugating activity. Appl Environ Microbiol. 1993;59:1120-1124.
44. Kim A, et al. Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis. J Am Diet Assoc. 2011;111:1720-1729.
45. Kong W, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351.
46. Kumar M, et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902-917.
47. Kwak JS, et al. Garlic powder intake and cardiovascular risk factors: a meta-analysis of randomized controlled clinical trials. Nutr Res Pract. 2014;8(6):644-654. doi: 10.4162/nrp.2014.8.6.644.
48. Lenz TL. Therapeutic lifestyle changes and pharmaceutical care in the treatment of dyslipid- emias in adults. J Am Pharm Assoc. 2005;45(4):492-499.
49. Li G, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol. 2012;258(2):268-274.
50. Lin YL, et al. Biologically active components and nutraceuticals in Monascus-fermented rice: a review. Appl Microbiol Biotechnol. 2008;77:965-973.
51. Liu J, et al. Chinese red yeast rice (monascus purpureus) for primary hyperlipidemia: a metaanalysis of randomized controlled trials. Chin Med. 2006;1:4.
52. Liu ZL, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011;(7):CD008305.
53. Macan H, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr. 2006;136(3 Suppl):793S-5.
54. Maciejko JJ, et al. Psyllium for the reduction of cholestyramine-associated gastrointestinal symptoms in the treatment of primary hypercholesterolemia. Arch Fam Med. 1994;3:955-960.
55. Mannarino MR, et al. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med. 2014;25(7):592-599. doi:10.1016/j.ejim.2014.06.008.
56. Marinangeli CP, et al. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr. 2010;50:259-267.
57. Martino F, et al. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis. 2005;15:174-180.
58. McCarty MF. Glucomannan minimizes the postprandial insulin surge: a potential adjuvant for hepatothermic therapy. Med Hypotheses. 2002;58(6):487-490.
59. McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr Atheroscler Rep. 2009;11:470-476.
60. Mechanick JI, et al. AACE Nutrition Guidelines Taskforce. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceu- ticals. Endocr Pract. 2003;9:417-470.
61. Mensink RP, et al. Plant stenols dose dependently decrease LDL cholesterol concentrations but not cholesterol standardized fat soluble antioxidant concentrations, at intakes up to 9g/d. Am J Clin Nutr. 2010;92:24-33.
62. Mogadishian MH, et al. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation. 1999;99:1733-1739.
63. Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamotpolyphenols: from animal models to human studies. Fitoterapia. 2011;82(3):309-316. doi: 10.1016/j.fitote.2010.10.014.
64. Moreyra AE, et al. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161-1166.
65. Morgan LM, et al. The effect of soluble- and insoluble-fibre supplementation on post-prandial glucose tolerance, insulin and gastric inhibitory polypeptide secretion in healthy subjects. Br J Nutr. 1990;64:103-110.
66. Moruisi KG, et al. Phytosterols/stanols lower cholesterol concentrations in familial hypercho- lesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr. 2006;25: 41-48.
67. Mullen E, et al. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr. 2004;134:2942-2947.
68. Nijjar PS, et al. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4(4):248-258.
69. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr. 1995;125(3 Suppl):606S-11.
70. Ras RT, et al. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214-219. doi:10.1017/S0007114514000750.
71. Ried K, et al. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71(5):282-299. doi:10.1111/nure.12012.
72. Samman S, et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. Am J Clin Nutr. 2001;73:607-612.
73. Scholle JM, et al. The effect of adding plant sterols or stanols to statin therapy in hypercholes- terolemic patients: systematic review and meta-analysis. J Am Coll Nutr. 2009;28:517-524
74. Shirashi M, et al. Association between serum folate levels and tea consumption during pregnancy. Biosci Trends. 2010;4:225-230.
75. Shrestha S, et al. A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake. J Nutr. 2007;137:1165-1170.
76. Singh DK, et al. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318:1020-1026.
77. Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep. 2001;3:47-53.
78. Sood N, et al. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008; 88(4):1167-1175.
79. Stock J. Focus on lifestyle: EAS Consensus Panel Position Statement on Phytosterol-added Foods. Atherosclerosis. 2014;234(1):142-145. doi:10.1016/j.atherosclerosis.2014.01.047.
80. Tokunaga S, et al. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol. 2002;12:157-165.
81. Torres N, et al. Regulation of lipid metabolism by soyprotein and its implication in diseases mediated by lipid disorders. J Nutr Biochem. 2006;17:365-373.
82. Trimarco B, et al. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab. 2011;4:133-140.
83. Vega-Lopez S, et al. Sex and hormonal status modulate the effects of psyllium on plasma lipids and monocyte gene expression in humans. J Nutr. 2003;133:67-70.
84. Vergara-Jimenez M, et al. Hypolipidemic mechanisms of pectin and pysllium in guinea pigs fed high fat-sucrose diets: alterations on hepatic cholesterol metabolism. J Lipid Res. 1998;39:1455-1465.
85. Vrzal R, et al. Activation of the arylhydrocarbon receptor by berberine in HepG2 and H4IIEcells: Biphasic effect on CYP1A1. Biochem Pharmacol. 2005;70:925-936.
86. Vuksan V, et al. Konjac-Mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. J Am Coll Nutr. 2001;20(S5):370S-80.
87. Weghuber D, Widhalm K. Effect of 3 month treatment of children and adolescents with familial and polygenic hypercholesterolemia with a soy-substituted diet. Br J Nutr. 2008;99: 281-286.
88. Wei ZH, et al. Time- and dose-dependent effect of psylium on serum lipids in mild- to- moderate hypercholesterolemia: a meta—analysis of controlled trials. Eur J Clin Nutr. 2009;63: 821-827.
89. Weingartner O, et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol. 2008;51(16):1553-1561.
90. Weingartner O, et al. Controversial role of plant sterol esters in the management of hypercho- lesterolaemia. Eur Heart J. 2009;30(4):404-409.
91. Weingartner O, et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/- mice. Cardiovasc Res. 2011;90(3):484-492.
92. Xin HW, et al. The effects of berberine on the pharmacokinetics of cyclosporine A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006;28:25-29.
93. Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712-717.
94. Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr Opin Lipidol. 2008;19(3):263-269.
95. Zheng XX, et al. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94:601-610.